Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era
Clinical Immunology · 2023
DOI: 10.1016/j.clim.2023.109656 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Immunology, 2023. Verfasst von Tomohito Sato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: COVID-19, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an autoimmune vasculitis characterized by the production of antibodies against ANCA, with unclear pathogenesis. With the ongoing COVID-19 pandemic, COVID-19 mRNA vaccination has been available in Japan since February 2021. Although autoimmune symptoms have been reported after COVID-19 vaccinations, there have been no clinical investigations regarding the relationship between COVID-19 mRNA vaccines and the pathogenesis of AAV. Thus, the present study aimed to investigate whether the administration of COVID-19 mRNA vaccines affects the development of AAV. The study identified patients with new-onset AAV who were MPO-ANCA or PR3-ANCA positive and met the entry criteria of the AAV EMA classification algorithm. The study compared the number of new AAV cases per year before and after the start of the COVID-19 mRNA vaccine program in Japan. The study found that the annual number of new cases of AAV in Japan's Nagasaki Prefecture increased by approximately 1.5-fold since the COVID-19 vaccine program was initiated, suggesting a possible link between the COVID-19 mRNA vaccines and the development of AAV. Although the study provides insight into the clinical evaluation and management of autoimmune symptoms following COVID-19 vaccination, further investigation of the possible association between COVID-19 mRNA vaccines and the pathogenesis of AAV is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Research Unit for Preventive and Clinical Medicine, Nagasaki University Graduate School of Biomedic…
- Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
- Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
- Department of Medical Virology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sato, T., Umeda, M., Sato, S., Michitsuji, T., Shimizu, T., Koga, T., Furuse, Y., & Kawakami, A. (2023). Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109656
Vancouver
Sato T, Umeda M, Sato S, Michitsuji T, Shimizu T, Koga T, et al. Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era. Clinical Immunology. 2023. doi:10.1016/j.clim.2023.109656
BibTeX
@article{Sato2023,
author = {Sato, Tomohito and Umeda, Masataka and Sato, Shuntaro and Michitsuji, Toru and Shimizu, Toshimasa and Koga, Tomohiro and Furuse, Yuki and Kawakami, Atsushi},
title = {Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era},
journal = {Clinical Immunology},
year = {2023},
doi = {10.1016/j.clim.2023.109656}
}
EUVIMED